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Abstract
Background: The recently identified member of the TNF superfamily TL1A (TNFSF15) increases IFN-c production by T cells in
peripheral and mucosal CCR9+ T cells. TL1A and its receptor DR3 are up-regulated during chronic intestinal inflammation in
ulcerative colitis and Crohn’s disease (CD). TL1A gene haplotypes increase CD susceptibility in Japanese, European, and US
cohorts.
Methodology and Principal Findings: Here we report that the presence of TL1A gene haplotype B increases risk in Jewish
CD patients with antibody titers for the E. coli outer membrane porin C (OmpC+) (Haplotype B frequency in Jewish CD
patients: 24.9% for OmpC negative and 41.9% for OmpC positive patients, respectively, P#0.001). CD14+ monocytes
isolated from Jewish OmpC+ patients homozygous for TL1A gene haplotype B express higher levels of TL1A in response to
FccR stimulation, a known inducing pathway of TL1A, as measured by ELISA. Furthermore, the membrane expression of
TL1A is increased on peripheral monocytes from Jewish but not non-Jewish CD patients with the risk haplotype.
Conclusions and Significance: These findings suggest that TL1A gene variation exacerbates induction of TL1A in response
to FccR stimulation in Jewish CD patients and this may lead to chronic intestinal inflammation via overwhelming T cell
responses. Thus, TL1A may provide an important target for therapeutic intervention in this subgroup of IBD patients.
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Introduction
TL1A, a recently identified member of the TNF superfamily,
increases IL-2 response by anti-CD3/CD28-stimulated T cells [1].
Furthermore, we and others have shown that TL1A synergizes
with IL-12 and IL-18 to augment IFN-c release in human T and
NK cells and biases T cell differentiation towards a TH1
phenotype [2,3,4]. TL1A expression is increased in inflamed
tissue of colon and small bowel of CD patients and colocalizes to
macrophages and T cells [2,5]. In particular, lamina propria, but
also peripheral CD4+CCR9+ T cells, constitutively express
membrane TL1A and are especially sensitive to TL1A stimulation
[3,4]. In murine models of ileitis, TL1A is mainly expressed on
lamina propria dendritic cells [6].
We have recently demonstrated that TL1A is produced by
antigen-presenting cells, e.g. monocytes and dendritic cells, in
response to FccR signaling but not in response to Toll-like
receptor agonists or pro-inflammatory cytokines [7]. Stimulation
with Immune Complexes (IC) leads to the expression of both
membrane and secreted TL1A [1,7]. Neutralizing TL1A antibod-
ies prevent and treat colitis in a murine model of chronic colitis by
affecting both TH1 and TH17 responses, suggesting that TL1A is a
central regulator of intestinal inflammation during colitis [8]. In
addition, it has been demonstrated recently that TL1A also plays
an important role in the pathogenesis of other inflammatory
diseases, such as Experimental Autoimmune Encephalomyelitis
(EAE) and allergic lung inflammation [9,10,11].
The first genome-wide association study of CD provided
evidence that variation in TNFSF15, the TL1A gene, contribute
to CD in Japanese and both CD and ulcerative colitis in the British
population [12,13]. Haplotypes composed of 5 TNFSF15 SNPs
were observed to confer significant CD risk (haplotype A) and
protection (haplotype B), using both case/control and family-based
study designs [12,13,14]. We have also observed a protective
association between CD and the same haplotype B in a Los Angeles
based cohort [15]. Stratification on Ashkenazi Jewish ethnicity
suggested that haplotype B may have a different effect on CD
susceptibility in the Jewish and non-Jewish populations. In contrast
to the protective association seen in non-Jews, the opposite trend
towards a risk association with haplotype B was observed in
Ashkenazi Jews [15]. Similar observation of differential genetic risk
association in diverse ethnic groups have been made in CD, in
ulcerative colitis and other gentically complex diseases including
schizophrenia and asthma [16,17,18,19,20,21,22]. Jewish CD
patients carrying the TNFSF15 haplotype B were more likely to have
more severe CD, as evidenced by a higher rate of surgery [15] and
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by the expression of antibody responses to microbial antigens,
including the E. coli outer membrane porin C (OmpC+) [23,24].
To date, no functional basis for the relationship between TNFSF15
variation and disease severity in CD patients has been shown.
In order to determine the functional consequences of TNFSF15
genetic variation, we have identified subjects for immunological
studies based on TNFSF15 haplotypes. Here we show that, in Jewish
CD patients with seropositivity for OmpC, the TL1A risk
haplotype TNFSF15 haplotype B is associated with higher TL1A
expression upon stimulation of FccR. Furthermore, Jewish but not
non-Jewish CD patients with the TNFSF15 risk haplotype B have a
higher baseline expression of TL1A on peripheral monocytes,
suggesting a higher baseline capacity for T cell stimulation.
Collectively, our data define a role for TNFSF15 genetic variation
in determining disease severity in Jewish CD patients, and support
the concept that TL1A is a novel interventional target, at least for
the subgroup of Jewish, OmpC+, CD patients.
Methods
Human subjects
We collected peripheral blood from randomly selected patients
attending the IBD center at Cedars-Sinai Medical Center who had
previously been diagnosed with CD according to standard clinical,
endoscopic, radiological, and histological findings. Written
informed consent was obtained from all patients. Procedures were
approved by the Institutional Review Board of Cedars-Sinai
Medical Center (IRB number 3358 and 2673). The patient’s
demographics, diagnoses and medications at time of sample
collection are provided in Table 1. The medications were
equivalent in the different groups. Jewish ethnicity was defined
as previously described by one or more grandparents of Ashkenazi
Jewish descent [25,26]. Controls were matched for ethnicity and
were usually spouses of CD patients.
TNFSF15 genotyping and haplotype assignment
Single nucleotide polymorphisms (SNPs) rs3810936, rs6478108,
rs6478109, rs7848647, and rs7869487 were genotyped using either
Illumina Golden Gate technology [27,28] or ABI TaqMan MGB
technology [29,30] following the manufacturer’s protocols (Illu-
mina, San Diego, CA; ABI, Foster City, CA). Assays for these
SNPs are available to other researchers through ABI as follows:
rs3810936, hCV363308; rs6478108, hCV170492; rs6478109,
hCV1305297; rs7848647, hCV11277159; and rs7869487,
hCV11277149. Consistency between the two methods has been
confirmed in our laboratory by genotyping over 200 samples with
both methods. Details of the positions of these SNPs with respect
to the TNFSF15 gene and the haplotypes from the individual SNPs
are shown in Figure 1. While redundancy in the 5 SNPs may be
apparent from Figure 1, all 5 SNPs are retained in this study in
order to (1) distinguish the major haplotypes from minor
haplotypes with low frequencies (data not shown) and (2) retain
the haplotype terminology of the previous reports [12,13,15].
Haplotypes were assigned from the individual SNP data using
Phase v2 and the probability of assignment was greater than 95%.
Association of haplotypes with the presence of antibody per subject
was tested by chi-square and the significance was estimated by
permutation (Jewish OmpC2: N= 304, Jewish OmpC+: N= 196,
non-Jewish OmpC2: N= 434, non-Jewish OmpC+: N= 234).
Serological Analysis
Sera were analyzed for expression of anti-OmpC antibodies by
ELISA as previously described [31].
Isolation of CD14+ monocytes from patient’s blood
Blood was obtained from patients after informed consent in
accordance with procedures established by the Cedars-Sinai
Institutional Review Board. Monocytes were isolated from PBMC
as described previously [7].
Cell culture and stimulation
Plate-bound, cross-linked human IgG (IC) was prepared as
described previously [7]. Monocytes were incubated with IC for
the indicated time-points.
ELISA
TL1A was quantified in undiluted supernatants from stimulated
cells using an ELISA and Ab developed at Teva Pharmaceutical
USA as described elsewhere [7].
Flow cytometry
Monocytes stimulated with IC or bacteria for 16 h were stained
with the TL1A Ab as described previously [7]. Cells were analyzed
on a CyAnTM ADP flow cytometer (Dako Cytomation, Carpin-
teria, CA) and analyzed with the Summit 4.1 software package
(Dako).
Statistics
Statistical significance between groups was determined by
Student’s t test. A value of p#0.05 was considered to be
statistically significant.
Results
Association of TNFSF15 (TL1A) haplotype B and the serum
expression of anti-OmpC in Jewish Crohn’s disease
patients
Since the expression of anti-OmpC in CD patients is a familial
trait and has been associated with severe CD [23,24,32], we tested
the association between TNFSF15 haplotype B and the serum
expression of anti-OmpC in Ashkenazi Jewish and non-Jewish CD
patients (Figure 1A–D). TNFSF15 haplotypes were assigned from
individual SNP data using PHASE v2 with a probability greater
than 95% (see Figure 1A–C for details of SNPs and haplotypes). In
non-Jewish CD subjects, there was no difference in the frequency
of haplotype B between OmpC positive and OmpC negative
subjects (OmpC negative 38.6%, OmpC positive 38.3%;
Figure 1D). The frequency of haplotype B in either group was
similar to that previously observed for all CD in non-Jewish
subjects [15]. In contrast, for Jewish CD subjects the frequency of
haplotype B was significantly higher in OmpC positive subjects
compared with OmpC negative subjects (Figure 1 D) (24.9%
OmpC negative, 41.9% OmpC positive, P#0.001). The frequency
of haplotype B in OmpC negative subjects was lower and in OmpC
positive subjects was higher than that previously observed for all
CD in Jewish subjects (32%) [15] (Figure 1D). In addition, the
level of anti-OmpC expression was higher in TNFSF15 (TL1A)
haplotype B Jewish subjects (the median level of anti-OmpC was
23.9 ELISA units in Jewish CD patients with haplotype B
compared with 14.9 in Jewish CD patients without haplotype B, P
wilcoxon test #0.001). The frequency of OmpC seropositivity in
Jewish CD patients with haplotype B is 52%, and 36% in non-Jewish
CD patients with haplotype B. We did not observe an association
between other CD-associated antibodies to microbial antigens (e.g.
anti-Cbir1 antibodies, anti-I2 antibodies, anti-ASCA antibodies)
and differences in haplotype B frequency in Jewish or non-Jewish
CD patients (data not shown).
TL1A Haplotypes and Expression
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4719
Table 1. Patient’s demographic, diagnoses, medications.
Ethnicity tnfsf15 haplotype_a tnfsf15 haplotype_b OMPC status Disease Activity Current IBD Medications
Jewish A A Positive Inactive Asacol
Jewish A A Positive Inactive Asacol, Purinethol
Jewish A A Positive Inactive Asacol, 6-MP
Jewish A A Positive Inactive Asacol, Remicade every 10 wks
Jewish A not B Positive Remicade
Jewish A A Positive Active Remicade
Jewish A A Positive Inactive Pentasa, 6-MP
Jewish not A B Positive Inactive Asacol. 6-MP
Jewish not A B Positive Inactive Budesonide
Jewish not A B Positive Active Remicade monthly
Jewish B B Positive Active Entocort
Jewish B B Positive Inactive 6-MP, Remicade every 3 months
Jewish B B Positive Prednisone, Pentasa
Jewish not A B Positive Active Mild-Moderate Asacol, 6-MP
Jewish A A negative Inactive 6-MP, Asacol, Remicade every
8 wks
Jewish A A negative Sulfasalazine
Jewish A A negative Pentasa
Jewish A A negative Active AZA
Jewish A A negative Active Mildly 6-MP, Asacol
Jewish A A negative Pentasa
Jewish A A negative Prednisone
Jewish A A negative 6-MP
Jewish A A negative Imuran, asulfidine
Jewish A A negative Asacol
Jewish B B negative None
Jewish B B negative Active Entocort, Colazal, Canasa supp.
Jewish B B negative None
Jewish B B negative Asathioprine
Jewish not A B negative Active Mildly Prednisone, 6-MP
Jewish not A B negative Pentasa
Jewish not A B negative Purinethol
non Jewish A A Positive Active None (Digest-tinol, aloe-based)
non Jewish A A Positive Active Mildly Imuran, Pentasa
non Jewish A A Positive None
non Jewish A A Positive Prednisone, Cipro, Xifaxin
non Jewish A A Positive Inactive None
non Jewish B B Positive Inactive Prednisone, Pentasa, Xifaxan
non Jewish B B Positive Inactive bordering active 6-MP, Pentasa, Remicade
non Jewish B B Positive Colazal
non Jewish B B Positive Active 6-MP, Pentasa, Thalidomide
non Jewish not A B Positive Entocort, 6-MP
non Jewish not A B Positive Remicade
non Jewish A A negative Inactive 6-MP
non Jewish A A negative Active Mildly Asacol, Remicade
non Jewish A A negative Active Humira
non Jewish A A negative Active Cansa supp.
non Jewish A A negative Active Asacol, 6-MP, Remicade
non Jewish A A negative Inactive AZA
non Jewish A A negative Inactive Asacol
TL1A Haplotypes and Expression
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TNFSF15 (TL1A) haplotypes in Jewish IBD patients results
in differential TL1A expression in monocytes stimulated
with IC
To determine if the different TNFSF15 (TL1A) haplotypes
associated with CD in Jewish patients correlate with functional
consequences in TL1A expression, we isolated CD14+ monocytes
from Jewish and non-Jewish CD patients with haplotypes A or B,
and stimulated them with immune complexes (IC), a known
inducer of TL1A gene expression [7]. We observed strong
induction of TL1A secretion in response to IC in Jewish haplotype
B carriers at 6 h of stimulation. Compared to Jewish haplotype A
carriers, the secretion was significantly increased at 6 h in haplotype
B carriers (Figure 2A). At 16 h we also observed an increase,
although not significant (p = 0.22), in secretion of TL1A in haplotype
B compared to haplotype A Jewish patients (Figure 2A). In non-
Jewish CD patients we also observed a significant difference
between TL1A secretion in haplotypes A and B at 6 h of IC
stimulation (Figure 2B). Haplotype B carriers secreted significantly
more TL1A at 6 h compared to haplotype A carriers. At 16 h the
difference in TL1A secretion between the haplotypes were not
significant (p = 0.29), although we observed a higher secretion in
haplotype B non-Jewish patients. To determine if there are ethnic
differences in expression of TL1A we compared Jewish and non-
Jewish haplotype B carriers. Jewish haplotype B carriers secreted
significant more TL1A at 6 h compared to non-Jewish haplotype B
(p = 0.002). At 16 h we did not observe any differences in the IC-
induced secretion of TL1A (p= 0.49). Next, we compared the
TL1A secretion in Jewish and non-Jewish haplotype A carriers.
There were no differences in the IC-induced secretion of TL1A in
Jewish or non-Jewish CD haplotype A patients at 6 or 16 h (p= 0.07
and 0.09, respectively).
To determine if the observed differences in TL1A secretion also
relate to differences in surface TL1A expression, we determined
the expression of membrane TL1A as measured by the percentage
of TL1A+ monocytes and mean fluorescence intensity (MFI) after
IC stimulation (Figure 3). We did not observe any significant
differences in the percentage of control or IC-stimulated TL1A+
monocytes in Jewish haplotype B carriers compared to haplotype A
carriers (Figure 3A, p= 0.19 and p= 0.49 for control and IC
stimulation, respectively). Furthermore, we also did not observe
any significant differences in the percentage of control or IC-
stimulated TL1A+ monocytes in non- Jewish haplotype B carriers
compared to haplotype A carriers (Figure 3B, p= 0.83 and p= 0.72
for control and IC stimulation, respectively). When we analyzed
MFI of TL1A staining we observed an increase in MFI in Jewish
haplotype B compared to haplotype A carriers, although this increase
did not reach significance (Figure 3C, p= 0.66 and p= 0.52 for
control and IC stimulation, respectively). We did not observe any
differences in MFI in non-Jewish haplotype B compared to haplotype
A carriers (Figure 3D, p= 0.56 and p= 0.91 for control and IC
stimulation, respectively). In summary, Jewish and non-Jewish
haplotype B carriers secrete significantly more TL1A in response to
IC compared to haplotype A carriers at 6 h (Table 2). Furthermore,
Jewish haplotype B carriers secrete significantly more TL1A
compared to non-Jewish haplotype B carriers (Figure 2C). In
contrast, we did not observe any significant differences in TL1A
surface expression in patients with different haplotypes in either
Jewish or non-Jewish CD patients (Table 2).
TNFSF15 (TL1A) haplotypes in Jewish OmpC+ IBD
patients result in differential TL1A expression in
monocytes stimulated with IC
Since we observed a risk association for TL1A haplotype B in
Jewish CD patients, and this association was accentuated in Jewish
OmpC+ patients, we subdivided the Jewish patients into OmpC+
and OmpC2 patients and analyzed TL1A secretion and
membrane expression for haplotypes A and B. We observed a
significant increase in TL1A secretion in patients carrying the B
haplotype compared to A carriers in Jewish OmpC+ patients in
response to IC (Figure 4A). Differences in TL1A secretion were
most prominent at 6 h post stimulation compared to 16 h
(Figure 4A, p= 0.34). We observed a TL1A response in Jewish
OmpC+ patients heterozygous for haplotype A and B that was
intermediate between that observed for patients carrying the A and
Table 1. cont.
Ethnicity tnfsf15 haplotype_a tnfsf15 haplotype_b OMPC status Disease Activity Current IBD Medications
non Jewish A A negative Inactive Prednisone
non Jewish A A negative Inactive Humira; Cipro, Flagyl
non Jewish A A negative Active Mildly None (other than curcumin,
vitamins)
non Jewish B B negative Active Prednisone, Humira
non Jewish not A B negative Active Remicade
non Jewish B B negative Active Mildly Pentasa, Remicade
non Jewish B B negative Active 6-MP, Pentasa, Entocort
non Jewish not A B negative Inactive 6-MP
non Jewish not A B negative Active Pentasa, Curcumin, Probiotics
non Jewish not A B negative Active Humira
non Jewish not A B negative Active Mildly Humira
non Jewish B B negative Inactive Remicade; prednisone
non Jewish B B negative Active Mildly Asacol, Prednisone
non Jewish not A B negative Active Mildly 6-MP, Asacol
non Jewish B B negative Active Mildly Remicade
doi:10.1371/journal.pone.0004719.t001
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B haplotype, respectively (data not shown). Jewish OmpC2 patients
carrying the B haplotype also secreted higher levels of TL1A in
response to IC than A carriers at 6 h post stimulation (Figure 4B,
p = 0.054 for 16 h IC stimulation), while non-Jewish OmpC+
patients with the B haplotype secreted higher levels of TL1A at 16 h
post stimulation (Figure 4C, p= 0.14 for 6 h IC stimulation),
suggesting different kinetics in the TL1A secretion in Jewish vs.
non-Jewish CD patients in response to FccR signaling. We did not
observe any differences in TL1A secretion in non-Jewish OmpC2
patients with the B haplotype compared to patients with haplotype A
(Figure 4D, p= 0.21 for 16 h IC stimulation).
Next, we analyzed the surface expression of TL1A in Jewish
OmpC+ patients with different haplotypes by flow cytometry
(Figure 5). We observed a significant increase in the proportion of
TL1A+ monocytes in untreated monocytes from Jewish patients
carrying the B haplotype compared to patients with the A haplotype in
Jewish patients regardless of their OmpC status (Figure 5A, B).
Similar differences were not seen in non-Jewish patients
(Figure 5C, D, p= 0.37 and p= 0.43 for non-Jewish OmpC+
and non-Jewish OmpC2 patients, respectively). Surprisingly, we
could not observe any differences in the percentage of monocytes
expressing TL1A stimulated with IC between different haplotypes
(Figure 5A, B, p= 0.31). However, the mean fluorescence intensity
(MFI) was significantly increased in IC stimulated monocytes in
Jewish OmpC+ patients carrying the B haplotype compared to A
carriers (Figure 5A) but not in Jewish OmpC2 patients (Figure 5B,
p = 0.35). We did not observe any significant differences in surface
expression of TL1A in untreated or IC stimulated monocytes
between A and B carriers in non-Jewish patients (Figure 5C, D,
Figure 2. The B risk haplotype is associated with increased
TL1A secretion in CD patients. Monocytes from Jewish and non-
Jewish patients with A, or B haplotypes were stimulated with IC for 6 or
16 h. Cell culture supernatants were analyzed for TL1A secretion by
ELISA. (A) Monocytes from Jewish patients with A or B haplotypes were
stimulated with IC for 6 or 16 h (n = 15 and 12 for haplotype A and
haplotype B, respectively, *, P#0.002). All data represent the mean6SD.
(B) Monocytes from non-Jewish patients with A or B haplotypes were
stimulated with IC for 6 or 16 h (n = 13 and 15 for haplotype A and
haplotype B, respectively, *, P#0.05).
doi:10.1371/journal.pone.0004719.g002
Figure 1. TL1A (TNFSF15) gene and haplotype structure and
association with Crohn’s Disease. (A) The TNFSF15 gene is on the
reverse strand of NCBI human genome build 36 at the position shown
on chromosome 9 but is shown 59 to 39 in keeping with the previous
reports. The dotted line represents genomic sequence, solid line the
gene sequence, thin bars untranslated regions, and thick bars the
exons. (B) Single nucleotide polymorphisms (SNPs) genotyped for this
study are listed with their relative positions along the gene. (C)
Definition of haplotypes assigned in this study. The nucleotide
assignments follow the previous report and correspond to the sense
strand of the gene. The numbers 26, 31, 35, 36, and 41 refer to previous
reports [12]. (D) Frequency of CD patients as a function of OmpC status
for TL1A haplotype B for Jewish and non-Jewish CD patients,
respectively (P#0.001).
doi:10.1371/journal.pone.0004719.g001
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p= 0.35 and p= 0.36 for IC-stimulated monocytes from non-
Jewish OmpC+ patients, % TL1A+ monocytes and MFI,
respectively, and p=0.68 and p= 0.74 for IC-stimulated mono-
cytes from non-Jewish OmpC+ patients, % TL1A+ monocytes
and MFI, respectively). In summary, Jewish OmpC+ and
OmpC2 haplotype B carriers secrete significantly more TL1A in
response to IC compared to haplotype A carriers (Table 3).
Furthermore, the proportion of TL1A+ monocytes in untreated
monocytes is significantly increased in Jewish OmpC+ and
OmpC2 haplotype B carriers compared to Jewish OmpC+ and
Figure 3. Haplotype A and B have similar TL1A surface expressions in Jewish and non-Jewish CD patients. (A) Monocytes from Jewish
patients with A or B haplotypes were stimulated with IC for 16 h. Monocytes were stained with an anti-TL1A antibody and analyzed by flow
cytometry. Data are presented as % of TL1A+ monocytes (n = 11 and 9 for haplotype A and haplotype B, respectively, P = 0.19 and P=0.49 for control
and IC, respectively). All data represent the mean6SD. (B) Monocytes from non-Jewish patients with A or B haplotypes were stimulated with IC for
16 h. Data are presented as % of TL1A+ monocytes (n = 14 and 16 for haplotype A and haplotype B, respectively, P = 0.83 and P=0.72 for control and
IC, respectively). (C) Monocytes from Jewish patients with A or B haplotypes were stimulated with IC for 16 h. Data are presented as mean
fluorescence intensity (MFI) (n = 11 and 9 for haplotype A and haplotype B, respectively, P = 0.66 and P= 0.52 for control and IC, respectively). (D)
Monocytes from non-Jewish patients with A or B haplotypes were stimulated with IC for 16 h. Data are presented as mean fluorescence intensity (MFI)
(n = 14 and 16 for haplotype A and haplotype B, respectively, P = 0.56 and P= 0.91 for control and IC, respectively).
doi:10.1371/journal.pone.0004719.g003
TL1A Haplotypes and Expression
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OmpC2 haplotype A carriers. Additionally, the MFI of TL1A
membrane expression was significantly increased in IC stimulated
monocytes in Jewish OmpC+ patients with the B haplotype
compared to patients with the A haplotype (Table 3).
Discussion
Our findings demonstrate a direct association between genetic
variation in the TL1A gene TNFSF15, and the induction of TL1A
in Jewish, and particularly in OmpC+ Jewish CD patients. Patients
carrying the TNFSF15 (TL1A) risk haplotype B have a significantly
increased expression of membrane and soluble TL1A in response
to IC. In the current era of finding genetic associations with
disease using genome-wide association studies, our report also
illustrates that detailed molecular phenotypic studies of patients
with particular haplotypes will lead to the discovery of important
functional differences that occur as a result of the different
haplotypes.
We have previously reported that TNFSF15 (TL1A) haplotype B is
associated with a more severe disease phenotype in Jewish
patients, as these individuals have a higher frequency of small
bowel surgery [15]. Furthermore, TNFSF15 haplotype B is
associated with increased risk of CD in Ashkenazi Jews (32% in
Table 2. Summary of significant differences for TL1A
haplotypes A and B in CD patients stratified into Jewish and
Non-Jewish
Jews Non-Jews
Soluble
TL1A
IC stimulation IC stimulation
haplotype B ... haplotype A** haplotype B . haplotype A*
*, p#0.05
**, p#0.005
doi:10.1371/journal.pone.0004719.t002
Figure 4. The B risk haplotype is associated with increased TL1A secretion in CD patient subgroups. (A) Monocytes from Jewish OmpC+
patients homozygous for haplotypes A or B were stimulated with IC for 6 or 16 h (n = 7 for haplotype A and haplotype B, *, P#0.001). Cell culture
supernatants were analyzed for TL1A by ELISA. (B) Monocytes from Jewish OmpC2 patients homozygous for haplotype A or haplotype B were
stimulated with IC for 6 or 16 h (n = 8 and 5 for haplotype A and haplotype B, respectively, *, P#0.05). (C) Monocytes from non-Jewish OmpC+ patients
with A or B haplotypes were stimulated with IC for 6 or 16 h (n = 4 and 5 for haplotype A and haplotype B, respectively, *, P#0.05). (D) Monocytes from
non-Jewish OmpC2 patients with A or B haplotypes were stimulated with IC for 6 or 16 h (n = 9 and 10 for A and B, respectively).
doi:10.1371/journal.pone.0004719.g004
TL1A Haplotypes and Expression
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Figure 5. The B risk haplotype is associated with an increase in the number of TL1A+ peripheral monocytes in Jewish but not in
non-Jewish CD patients. (A) Monocytes from Jewish OmpC+ patients with A or B haplotypes were stimulated with IC for 16 h. Monocytes were
stained with an anti-TL1A antibody and analyzed by flow cytometry. Data are presented as % of TL1A+ monocytes (left panel) or mean fluorescence
intensity (MFI) (right panel) (n = 6, or 7 for haplotype A or haplotype B, respectively, *, P#0.05 for % TL1A+; *, P#0.02 for MFI). (B) Monocytes from
Jewish OmpC2 patients with A or B haplotypes were stimulated with IC for 16 h. Data are presented as % of TL1A+ monocytes (left panel) or MFI
(right panel). (n = 9 or 6 for haplotype A or haplotype B, respectively, *, P#0.05) (C) Monocytes from non-Jewish OmpC+ patients with A or B
haplotypes were stimulated with IC for 16 h. Data are presented as % of TL1A+ monocytes (left panel) or MFI (right panel). (n = 5 or 6 for haplotype A
or haplotype B, respectively). (D) Monocytes from non-Jewish OmpC2 patients with A or B haplotypes were stimulated with IC for 16 h. Data are
presented as % of TL1A+ monocytes (left panel) or MFI (right panel). (n = 9 or 11 for haplotype A or haplotype B, respectively).
doi:10.1371/journal.pone.0004719.g005
TL1A Haplotypes and Expression
PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4719
CD vs. 26% in controls) but with a decreased risk in non-Jewish
CD patients (39% in CD vs. 50% in controls) [15]. Here, we
extend our findings and demonstrate that Jewish OmpC+ CD
patients (a group characterized by more severe disease) have a
further increased frequency of haplotype B (also a group
characterized by more severe disease) (42% CD OmpC+ vs.
25% CD OmpC2) suggesting that an antibody titer for the E. coli
outer membrane porin C (OmpC) increases the risk of CD in
Jewish patients carrying the B haplotype. We observed that this
hierarchical relationship of TL1A risk haplotype B and OmpC titers
in Jewish CD patients also applies to the functional response, e.g.
the immune responses to FccR signaling in Jewish CD patients. In
both Jewish and non-Jewish CD we observed a significant increase
of TL1A secretion in haplotype B compared to haplotype A. However,
we observed an earlier onset of TL1A secretion and an overall
greater amount of TL1A secretion in Jewish patients with haplotype B
compared to non-Jewish haplotype B carriers, suggesting different
kinetics in the induction of TL1A expression in Jewish vs. non-Jewish
patients carrying haplotype B (see Table 2 for data summary). When
we further sub-stratified Jewish and non-Jewish patients into patient
groups with or without positive serology for OmpC antibodies, this
association of TL1A haplotype B and increased TL1A expression was
further accentuated in Jewish OmpC+ patients. Jewish OmpC+
patients with haplotype B have increased secretion of soluble and
enhanced expression of membrane TL1A in response to IC, as well
as increased baseline membrane TL1A expression, when compared
to haplotype A (see Table 3 for data summary). On the other hand
Jewish OmpC2 patients with haplotype B have increased secretion of
soluble TL1A in response to IC, and increased baseline membrane
TL1A expression, but TL1A and membrane TL1A in response to
IC are not significantly different when compared to haplotype A. In
non-Jewish OmpC+ patients with haplotype B, we only observed an
increased secretion of soluble TL1A in response to IC, but with a
distinct and delayed kinetics compared to Jewish OmpC+ and
OmpC2 patients of the same haplotype. The higher baseline
expression of membrane TL1A on monocytes that we observed in
Jewish but not non-Jewish CD patients carrying haplotype B might
suggest a higher capacity of TL1A dependent T cell activation in
these patients [5,7].
Interestingly, we observed that the percentages of monocytes
with TL1A surface expression being approximately twice as high
in OmpC2 Jewish patients compared to OmpC+ patients for
either haplotype when stimulated with IC (Figures 5A, B). We
analyzed the TL1A surface expression of monocytes in response to
IC stimulation at a 16 h time-point. We have demonstrated that
monocytes from Jewish OmpC+ and OmpC2 patients have a
faster induction of TL1A secretion compared to non-Jewish
patients (Figures 2, 4). We observed maximal induction of TL1A
secretion in Jewish OmpC+ patients at 6 h and a decline of TL1A
secretion at 16 h. However, in Jewish OmpC2 patients we
observed a further increase of TL1A secretion at 16 h (Figure 4 A
and B). The mechanism for the differential induction in Jewish
OmpC+ vs. Jewish OmpC2 and Jewish vs. non-Jewish patients is
currently unknown. The differences in surface expression in Jewish
OmpC+ vs. OmpC2 patients might therefore just reflect the
differences in cleavage-kinetics of TL1A from the membrane due
to higher turn-over of TL1A in Jewish OmpC+ patients.
We previously published that TNFSF15 haplotype B is associated
with increased risk of CD in Ashkenazi Jews but with a decreased risk
in non-Jewish CD patients [15]. To our surprise, we did not observe a
decrease in TL1A expression in haplotype B carriers in non-Jewish
patients compared to haplotype A carriers as one would expect
(Figures 2B, 3B, 3D). However, from the data presented here we are
concluding that Jewish CD patients demonstrate a faster TL1A
induction than non-Jewish patients. We observed an increase of
TL1A secretion at 16 h compared to 6 h post IC-stimulation in non-
Jewish patients suggesting a maximal secretion at 16 h. However, we
did not analyze the TL1A secretion beyond the 16 h time-point and
it might be possible that in non-Jewish patients the maximal secretion
of TL1A is reached beyond 16 h. Therefore, it cannot be excluded
that a difference between TL1A secretion in haplotype A and Bmight
occur at a later time-point in non-Jewish patients. Furthermore, based
on our data we hypothesize that TL1A is a CD severity more
importantly than susceptibility gene. We have previously demon-
strated that TNFSF15 haplotype B is associated with increased risk of
CD in Jews but with a decreased risk in non-Jewish CD patients [15].
However, when we analyzed haplotype association with disease
severity, as measured by clinical parameters (fibrostenosis, internal
perforation, perianal penetration, small bowel surgeries), no associ-
ation was observed between haplotypes in non-Jewish patients but
association was observed in Jewish CD patients carrying haplotype B
[15]. These data are consistent with our findings of no significant
differences in TL1A expression in non-Jewish patients.
The TNFSF15 genetic variation and TL1A functional changes
observed here are of importance in the context of the recent
demonstration that the IL23R gene is a major determinant of CD
susceptibility [14,33,34,35,36,37,38,39]. In particular, we have
been able to demonstrate that TL1A synergizes with IL-23 to
Table 3. Summary of significant differences for TL1A haplotypes A and B in CD patients sub-stratified into Jewish OmpC+/OmpC2
and non-Jewish OmpC+/OmpC2
Jews OmpC+ Jews OmpC2 Non-Jews OmpC+ Non-Jews OmpC2
Soluble TL1A IC stimulation IC stimulation IC stimulation IC stimulation
haplotype B . haplotype A*** haplotype B . haplotype A* haplotype B . haplotype A* —
Membrane TL1A
(% TL1A+ Monocytes) baseline baseline baseline baseline
haplotype B . haplotype A * haplotype B . haplotype A * — —
(MFI) IC stimulation IC stimulation IC stimulation IC stimulation
haplotype B . haplotype A ** — — —
*, p#0.05
**, p#0.01
***, p#0.001
doi:10.1371/journal.pone.0004719.t003
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induce IL-17 production by CD4+ T cells in a mouse model of
chronic colitis [8]. Furthermore, these observations are consistent
with the role of TL1A during the development of chronic colitis in
mice. We have been able to demonstrate that administration of
neutralizing TL1A antibodies not only prevents but also treats
established chronic colitis, likely by directly blocking IFN-c
production by TH1 cells and IL-17 and IL-6 production from
TH17 cells, and also by blocking the enhancing effect of TL1A/IL-
12 and TL1A/IL-23 on these CD4+ T cell subsets [8]. These data
support the notion that TL1A expression is increased during
chronic mucosal inflammation and that leads to further activation
of TH1 and TH17 cells.
In this study, we demonstrated that there is a direct association
between genetic variants of the TL1A gene and the induction of
TL1A in Jewish CD patients. Since the induction of TL1A gene
expression seems to be restricted to stimulation by FccR signaling
and/or enteric bacteria [7,40,41], blockage of TL1A might have
therapeutic benefit in IBD patients without markedly increasing
the susceptibility to infection. Defining CD patients by ethnicity,
serotyping, and genotyping, will allow us to identify patients with
the potential for higher TL1A response to immune complexes and
commensal bacteria and hence may well identify those CD
patients that would respond best to therapeutic blockade of TL1A
function.
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